James Huang bought $4.0M of Connect Biopharma Holdings Limited (CNTB)
Executed Mar 31, disclosed Apr 1, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Apr 1), the stock returned -7.1% (delay-adjusted); from the execution session (Mar 31), -9.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
James Huang (Director) filed 4 Form 4 reports in the trailing twelve months (2 purchases, 2 sales), most often in Atara Biotherapeutics, Inc. (ATRA). Across 2 priced purchase filings, the average 21-session return was -4.9% from execution and -2.5% from disclosure (delay-adjusted; derived). The largest single filing was $4.0M of CNTB (1,160,000 sh × $3.45, as filed), executed Mar 31.
Healthcare · Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→150,000 sh × $2.48
Exec May 29
Filed Jun 2 · 4:30 PM ET